Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Sexuality and the management of BPH with alfuzosin (SAMBA) trial

Abstract

The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Qmax, IPSS and IIEF-15 were checked at baseline and end point. At the end point, Qmax (+4.7 ml s−1, P<0.01) and IPSS (−5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1–94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3–28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hoesl CE, Woll EM, Burkart M, Altwein JE . Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511–517.

    Article  CAS  PubMed  Google Scholar 

  2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  PubMed  Google Scholar 

  3. Rosen RC, Giuliano F, Carson CC . Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824–837.

    Article  PubMed  Google Scholar 

  4. Vallancien G, Emberton M, Harving N, van Moorselaar RJ . Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–2261.

    Article  PubMed  Google Scholar 

  5. Brannigan RE . Ejaculatory disorders and lower urinary tract symptoms. Curr Urol Rep 2004; 5: 280–286.

    Article  PubMed  Google Scholar 

  6. Terai A, Ichioka K, Matsui Y, Yoshimura K . Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 2004; 64: 132–136.

    Article  PubMed  Google Scholar 

  7. Kirby RS . Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 33 (Suppl 2): 19–27.

    Article  CAS  PubMed  Google Scholar 

  8. Roehrborn CG . Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953–959.

    Article  CAS  PubMed  Google Scholar 

  9. van Kerrebroec P, Jardin A, van Cangh P, Laval KU . Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002; 41: 54–60; discussion 60–61.

    Article  CAS  PubMed  Google Scholar 

  10. Rosen R, Seftel A, Roehrborn CG . Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 2007; 19: 480–485.

    Article  CAS  PubMed  Google Scholar 

  11. van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603–608.

    Article  PubMed  Google Scholar 

  12. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    Article  PubMed  Google Scholar 

  13. Kirby RS, O'Leary MP, Carson C . Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005; 95: 103–109; discussion 109.

    Article  CAS  PubMed  Google Scholar 

  14. Zlotta AR, Teillac P, Raynaud JP, Schulman CC . Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005; 48: 269–276.

    Article  CAS  PubMed  Google Scholar 

  15. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD . Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777–782.

    Article  PubMed  Google Scholar 

  16. Oh CY, Lee JS, Chung BH . A validation and reliability study for the Korean version of the male sexual health questionnaire. Korean J Urol 2005; 46: 1308–1326.

    Google Scholar 

  17. Hofner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ . Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335–341.

    Article  CAS  PubMed  Google Scholar 

  18. Nickel JC, Elhilali M, Emberton M, Vallancien G . The beneficial effect of alfuzosin 10 mg once daily in ‘real-life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int 2006; 97: 1242–1246.

    Article  CAS  PubMed  Google Scholar 

  19. Traish AM, Netsuwan N, Daley J, Padman-Nathan H, Goldstein I, Saenz de Tejada I . A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1995; 153: 222–227.

    Article  CAS  PubMed  Google Scholar 

  20. van Dijk MM, de la Rosette JJ, Michel MC . Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006; 66: 287–301.

    Article  CAS  PubMed  Google Scholar 

  21. Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J . A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 605–608.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The SAMBA trial was sponsored by Sanofi-Aventis/Handok pharmacy Inc., Korea.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B-H Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, BH., Lee, JY., Kim, CI. et al. Sexuality and the management of BPH with alfuzosin (SAMBA) trial. Int J Impot Res 21, 68–73 (2009). https://doi.org/10.1038/ijir.2008.62

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.62

Keywords

This article is cited by

Search

Quick links